These findings suggest that topical OSE treatment modulates allergic inflammatory reactions in oxazolone-induced ACD by suppressing IgE secretion, subsequently reducing local mast cell recruitment, and consequently, decreasing IL-5 levels in the affected skin area. This evidence concerns the gene IGHE and granular corneal dystrophy type II.